Navigation Links
Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation
Date:3/14/2012

RALEIGH, N.C., March 14, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the New Jersey Federal Court has granted a stay of further litigation in the patent infringement lawsuit previously filed by MonoSol Rx, LLC (MonoSol).  The court ordered that the case would be stayed pending resolution by the U.S. Patent and Trademark Office (USPTO) of reexamination proceedings and follows the recent rejection by the USPTO of all claims in all three patents asserted by MonoSol against BDSI and its commercial partners for ONSOLIS. 

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )

Should the USPTO uphold its initial decisions, the MonoSol patents will be rendered invalid, supporting BDSI's assertion that MonoSol's claims from the beginning had no merit.  BDSI is pleased that the court will await the outcome of the USPTO's actions prior to conducting further proceedings in this case.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence.  BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo Pharmaceuticals.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the Company's litigation with MonoSol and further action taken by the Company before the USPTO in connection therewith) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
2. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
3. State, Federal Officials Remind Health Care Workers, Other at-Risk Individuals to Get Annual Flu Shot
4. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
5. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
6. Southern Research to Play Key Role in the Federal Governments Search for New Cancer Therapies
7. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
8. Faced With Federal Prosecution, MountainView Agrees to Stop Harassment of RNs in Settlement With Labor Board
9. Malaria Experts Call on Federal Government to Increase Support for Research and Development
10. Federal Judge Rejects GlaxoSmithKlines Claims of Privilege
11. Chesley Files Federal Zicam Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. , ... tests, has received two prestigious recognitions that acknowledge the promise of its PWS ... Preora has been named a Top 100 Finalist for the 16th annual Chicago ...
(Date:9/21/2017)... ... September 21, 2017 , ... A ... addiction recovery at a time when Virginia faces an opioid epidemic. ... a staggering increase of 38 percent from 2015, underscoring the need for additional ...
(Date:9/21/2017)... TX (PRWEB) , ... September 21, 2017 , ... ... senior housing operators, announces the acquisition of Isle at Kingwood Assisted Living and ... Kingwood is an established retirement community with 55 assisted living apartments, 43 memory ...
(Date:9/21/2017)... ... September 21, 2017 , ... In the inaugural 30-minute ... Emeritus Professor of Education Gregory A. Smith examines student privacy issues with University ... Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . , Join ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ... (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the launch of ... easy access to essential information that offers a more comprehensive understanding of the ...
Breaking Medicine News(10 mins):